Bacterial meningitis: A review of effective pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 10, 2007, Pages 1493-1504

  Weisfelt, Martijn ^a   de Gans, Jan ^a   van de Beek, Diederik ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial therapy; Bacterial meningitis; Dexamethasone; Neisseria meningitidis; Streptococcus pneumoniae

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; DEXAMETHASONE; ERTAPENEM; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ADJUVANT THERAPY; ADRENAL INSUFFICIENCY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL MENINGITIS; BACTERIOSTASIS; BLOOD BRAIN BARRIER; BRAIN VENTRICULITIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEARING LOSS; HUMAN; LISTERIA MONOCYTOGENES; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ADULT; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; MENINGITIS, BACTERIAL; TREATMENT OUTCOME;

EID: 34447499928     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.10.1493     Document Type: Review

References (70)

1. TUNKEL AR: Bacterial Meningitis. Lippincott Williams & Wikinson, Philadelphia (2001).
2. HAUSDORFF WP, FEIKIN DR, KLUGMAN KP: Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis. (2005) 5:83-93.
3. SWARTZ MN: Bacterial meningitis - a view of the past 90 years. N. Engl. J. Med. (2004) 351:1826-1828.
4. VAN DE BEEK D, DE GANS J, TUNKEL AR, WIJDICKS EF: Community-acquired bacterial meningitis in adults. N. Engl. J. Med. (2006) 354:44-53.
5. SCHUCHAT A, ROBINSON K, WENGER JD et al.: Bacterial meningitis in the United Scares in 1995. Active Surveillance Team. N. Engl. J. Med. (1997) 337:970-976.
6. DURAND ML, CALDERWOOD SB, WEBER DJ et al.: Acute bacterial meningitis in adults. A review of 493 episodes. N. Engl. J. Med. (1993) 328:21-28.
7. VAN DE BEEK D, DE GANS J, SPANJAARD L, WEISFELT M, REITSMA JB, VERMEULEN M: Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med. (2004) 351:1849-1859.
8. SAEZ-LLORENS X, MCCRACKEN GH JR: Bacterial meningitis in children. Lancet (2003) 361:2139-2148.
9. PELTOLA H: Worldwide Haemaphilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. (2000) 13:302-317.
10. SHORT WR, TUNKEL AR: Changing epidemiology of bacterial meningitis in the United States. Curr. Infect. Dis. Rep. (2000) 2:327-331.
11. FITCH MT, VAN DE BEEK D: Emergency diagnosis and treatment of adult meningitis. Lancet Infect. Dis. (2007) 7:191-200.
12. KYAW MH, LYNFIELD R, SCHAFFNER W et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. (2006) 354:1455-1463.
13. SNAPE MD, POLLARD AJ: Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. (2005) 5:21-30.
14. WHITNEY CG, FARLEY MM, HADLER J et al.: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. (2000) 343:1917-1924.
15. BUTLER JC, DOWELL SF, BREIMAN RF: Epidemiology of emerging pnecumococcal drug resistance: implications for treatment and prevention. Vaccine (1998) 16:1693-1697.
16. WEISFELT M, DE GANS J, VAN DER POLL T, VAN DE BEEK D: Pneumococcal meningitis in adults: new approaches to management and prevention. Lancet Neurol. (2006)5:332-342.
17. KASTENBAUER S, PFISTER HW: Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain (2003) 126:1015-1025.
18. BRUYN GA, KREMER HP, DE MARIE S, PADBERG GW, HERMANS J, VAN FURTH R: Clinical evaluation of pneumococcal meningitis in adults over a twelve-year period. Eur. J. Clin. Microbiol. Infect. Dis. (1989) 8:695-700.
19. HOEN B, VIEL JF, GERARD A, DUREUX JB, CANTON P: Mortality in pneumococcal meningitis: a multivariate analysis of prognostic factors. Eur. J. Med. (1993) 2:28-32.
20. AUBURTIN M, PORCHER R, BRUNEEL F et al.: Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am. J. Respir. Crit. Care Med. (2002) 165:713-717.
21. ATTIA J, HATALA R, COOK DJ, WONG JG: The rational clinical examination. Does this adult patient have acute meningitis? JAMA (1999) 282:175-181.
22. VAN DE BEEK D, SCHMAND B, DE GANS J et al.: Cognitive impairment in adults with good recovery after bacterial meningitis. J. Infect. Dis. (2002) 186:1047-1052.
23. HOOGMAN M, VAN DE BEEK D, WEISFELT M, DE GANS J, SCHMAND B: Cognitive outcome in adults after bacterial meningitis. J. Neurol. Neurosurg. Psychiatry (In Press) (E-pub).
24. PROULX N, FRECHETTE D, TOYE B, CHAN J, KRAVCIK S: Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM (2005) 98:291-298.
25. ARONIN SI, PEDUZZI P, QUAGLIARELLO VJ: Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann. Intern. Med. (1998) 129:862-869.
26. AUBURTIN M, WOLFF M, CHARPENTIER J et al.: Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit. Care Med. (2006) 34:2758-2765.
27. VAN DE BEEK D, DE GANS J, SPANJAARD L, VERMEULEN M, DANKERT J: Antibiotic guidelines and antibiotic use in adult bacterial meningitis in The Netherlands. J. Antimicrob. Chemother. (2002) 49:661-666.
28. LUTSAR I, MCCRACKEN GH JR, FRIEDLAND IR; Antibiotic pharmacodynamics in cerebrospinal fluid. Clin. Infect. Dis. (1998) 27:1117-1127.
29. ANDES DR, CRAIG WA: Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect. Dis. Clin. North Am. (1999) 13:595-618.
30. SCHMIDT T, TAUBER MG: Pharmacodynamics of antibiotics in the therapy of meningitis: infection model observations. J. Antimicrob. Chemother. (1993) 31(Suppl. D):61-70.
31. SINNER SW, TUNKEL AR: Antimicrobial agents in the treatment of bacterial meningitis. Infect. Dis. Clin. North Am (2004) 18:581-602.
32. VAN DE BEEK D, DE GANS J: Dexamethasone in adults with community-acquired bacterial meningitis. Drugs (2006) 66:415-427.
33. KOEDEL U, SCHELD WM, PFISTER HW: Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect. Dis. (2002) 2:721-736.
34. AKIRA S: Toll-like receptors and innate immunity. Adv. Immunol. (2001) 78:1-56.
35. MATTIE DH, STUERTZ K, NAU R, VAN DISSEL JT: Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniae. J. Antimicrob. Chemother. (2005)56(1):154-159.
36. BRINK M, HAGBERG L: Outcome of 8-hour dosing intervals with β-lactam antibiotics in adult acute bacterial meningitis. Scand. J. Infect. Dis. (2006) 38:772-777.
37. ROBERTS JA, BOOTS R, RICKARD CM et al.: Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J. Antimicrob. Chemother. (2007) 59:285-291.
38. TUNKEL AR, HARTMAN BJ, KAPLAN SL et al.: Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. (2004) 39:1267-1284.
39. PFAUSLER B, SPISS H, BEER R et al.: Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J. Neurosurg. (2003) 98:1040-1044.
40. MCCRACKEN GH JR, MIZE SG: A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the Neonatal Meningitis Cooperative Study Group. J. Pediatr. (1976) 89:66-72.
41. MCCRACKEN GH JR, MIZE SG, THRELKELD N: Inttraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet (1980) 1:787-791.
42. MANDEL G, BENNETT J, DOLIN R: Principles and Practice of Infectious Diseases (6 edn). Churchill Livingston, New York (2005).
43. LATORRE C, GENE A, JUNCOSA T, MUNOZ C, GONZALEZ-CUEVAS A: Neisseria meningitidis: evolution of penicillin resistance and phenotype in a children's hospital in Barcelona, Spain. Acta Paediatr. (2000) 89:661-665.
44. CUBELLS CL, GARCIA JJG, MARTINEZ JR, OTIN CL: Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr. (1997) 86:26-29.
45. SCHELD WM, DACEY RG, WINN HR, WELSH JE, JANE JA, SANDE MA: Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J. Clin. Invest. (1980) 66:243-253.
46. TAUBER MG, KHAYAM-BASHI H, SANDE MA: Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J. Infect. Dis. (1985) 151:528-534.
47. SCHELD WM, KOEDEL U, NATHAN B, PFISTER HW: Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis. (2002) 186 (Suppl. 2):S225-S233.
48. VAN DE BEEK D, DE GANS J, MCINTYRE P, PRASAD K: Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. (2007) (1):CD004405.
49. MCINTYRE PB, BERKEY CS, KING SM et al.: Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA (1997) 278:925-931.
50. DE GANS J, VAN DE BEEK D: Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med. (2002) 347:1549-1556.
51. VAN DE BEEK D, DE GANS J: Dexamethasone and pneumococcal meningitis. Ann. Intern. Med. (2004) 141:327.
52. VAN DE BEEK D, DE GANS J, MCINTYRE P, PRASAD K: Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect. Dis. (2004) 4:139-143.
53. WEISFELT M, VAN DE BEEK D, DE GANS J: Dexamethasone treatment in adults with pneumococcal meningitis: risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. (2006) 25(2):73-78.
54. VAN DE BEEK D: The brainteasing effect of dexamethasone. Lancet Neurol. Dis. (2007) 6:203-204.
55. ANNANE D, SEBILLE V, CHARPENTIER C et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288:862-871.
56. COOPER MS, STEWART PM: Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. (2003) 348:727-734.
57. CRONIN L, COOK DJ, CARLET J, HEYLAND DK et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. (1995) 23:1430-1439.
58. PARIS MM, HICKEY SM, USCHER MI, SHELTON S, OLSEN KD, MCCRACKEN GH JR: Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. (1994) 38:1320-1324.
59. RICARD JD, WOLFF M, LACHERADE JC et al.: Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin. Infect. Dis. (2007) 44:250-255.
60. LEIB SL, HEIMGARTNER C, BIFRARE YD, LOEFFLER JM, TAAUBER MG: Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr. Res. (2003) 54:353-357.
61. SPREER A, GERBER J, HANSSEN MS et al.: Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr. Res. (2006) 60:210-215.
62. WEISFELT M, HOOGMAN M, VAN DE BEEK D, DE GANS J, DRESCHLER WA, SCHMAND BA: Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann. Neurol. (2006) 60:456-468.
63. BUTLER JC, SHAPIRO ED, CARLONE GM: Pneumococcal vaccines: history, current status, and future directions. Am. J. Med. (1999) 107:S69-S76.
64. SWIATLO E, WARE D: Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol. Med. Microbiol. (2003) 38:1-7.
65. KNAUST A, FROSCH M: Genome-based vaccines. Int. J. Med. Microbiol. (2004) 294:295-301.
66. KIM KS: Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat. Rev. Neurosci. (2003) 4:376-385.
67. VAN DE BEEK D, WEISFELT M, DE GANS J, TUNKEL AR, WIJDICKS EF: Drug insight: adjunctive therapies in adults with bacterial meningitis. Nat. Clin. Pract. Neurol. (2006) 2:504-516.
68. KASTENBAUER S: Pneumococcal meningitis: a 21st century perspective. Lancet Neurol. (2006) 5:104-105.
69. WEISFELT M, VAN DE BEEK D, SPANJAARD L, REITSMA JB, DE GANS J: Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol. (2006) 5:123-129.
70. WEISFELT M, VAN DE BEEK D, SPANJAARD L, REITSMA JB, DE GANS J: Community-acquired bacterial meningitis in older people. J. Am. Geriatr. Soc. (2006) 54:1500-1507.